Acceleron's pulmonary hypertension treatment meets main goal, shares soar 53%

(Reuters) – Acceleron Pharma Inc (O:) said on Monday its investigational treatment for pulmonary arterial hypertension met the main goal in a mid-stage trial, sending its shares surging 53%.

The treatment, sotatercept, showed significant reduction in pulmonary vascular resistance versus placebo at week 24.

Pulmonary arterial hypertension, or PAH, occurs when arteries in the lungs constrict, forcing the heart to work harder and potentially leading to heart failure. Its symptoms include shortness of breath and fatigue.

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.